DOCSLIB.ORG

Combination OX40 Agonism/CTLA-4 Blockade with HER2 Vaccination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination OX40 Agonism/CTLA-4 Blockade with HER2 Vaccination Combination OX40 agonism/CTLA-4 blockade PNAS PLUS with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice Stefanie N. Lincha, Melissa J. Kasiewicza, Michael J. McNamaraa, Ian F. Hilgart-Martiszusa, Mohammad Farhada,b, and William L. Redmonda,1 aRobert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213; and bCell, Developmental, and Cancer Biology Department, Oregon Health and Science University, Portland, OR 97239 Edited by Laurence Zitvogel, Institut Gustave Roussy-France, Villejuif Cedex, France, and accepted by the Editorial Board December 7, 2015 (received for review June 26, 2015) Immunotherapy is gathering momentum as a primary therapy for of preclinical models. Treatment with an agonist aOX40 mAb cancer patients. However, monotherapies have limited efficacy in directly stimulated CD4 and CD8 T cells and induced their improving outcomes and benefit only a subset of patients. Combina- expansion, differentiation, and up-regulation of prosurvival mole- tion therapies targeting multiple pathways can augment an immune cules (7–12). Moreover, OX40 ligation promoted the generation response to improve survival further. Here, we demonstrate that dual of long-lived memory CD8 T cells and enhanced their function. aOX40 (anti-CD134)/aCTLA-4 (anti–cytotoxic T-lymphocyte–associated Recent data indicate that combined aOX40/aCTLA-4 therapy protein 4) immunotherapy generated a potent antigen-specific CD8 induced a robust effector CD4 and CD8 T-cell response necessary T-cell response, enhancing expansion, effector function, and memory for tumor regression and significantly improved the survival of T-cell persistence. Importantly, OX40 and CTLA-4 expression on CD8 tumor-bearing hosts relative to therapy with either agent alone T cells was critical for promoting their maximal expansion following (13). Despite this success, the response to combination aOX40/ combination therapy. Animals treated with combination therapy aCTLA-4 treatment was greatly diminished in more established – and vaccination using anti DEC-205 (dendritic and epithelial cells, tumors. This therapy may be unable to overcome T-cell anergy – 205 kDa) HER2 (human epidermal growth factor receptor 2) had sig- in more established immunosuppressive tumor microenviron- nificantly improved survival in a mammary carcinoma model. Vacci- ments, possibly because it is ineffective at specifically targeting nation with combination therapy uniquely restricted Th2-cytokine and expanding tumor-reactive T cells and relies on limited or production by CD4 cells, relative to combination therapy alone, and defective endogenous priming by dendritic cells (14). Currently, enhanced IFNγ production by CD8 and CD4 cells. We observed an in- clinically tested vaccines targeting cross-presenting dendritic cells crease in MIP-1α (macrophage inflammatory protein-1α)/CCL3 [chemo- [i.e., anti–DEC-205 (dendritic and epithelial cells, 205 kDa) mAb kine (C-C motif) ligand 3], MIP-1β/CCL4, RANTES (regulated on conjugated to tumor antigens] have demonstrated promise by activation, normal T-cell expressed and excreted)/CCL5, and GM-CSF – production by CD8 and CD4 T cells following treatment. Furthermore, priming a more robust cytotoxic T-cell response (15 19). The this therapy was associated with extensive tumor destruction and possibility remains that increased Th2-cytokine production by T-cell infiltration into the tumor. Notably, in a spontaneous model of CD4 T cells following combination therapy may reduce its prostate adenocarcinoma, vaccination with combination therapy re- versed anergy and enhanced the expansion and function of CD8 T cells Significance recognizing a tumor-associated antigen. Collectively, these data dem- onstrate that the addition of a vaccine with combined aOX40/aCTLA-4 Several immunotherapies are approved for treating cancer pa- immunotherapy augmented antitumor CD8 T-cell function while limit- tients, including aCTLA-4 (anti–cytotoxic T-lymphocyte–asso- ing Th2 polarization in CD4 cells and improved overall survival. ciated protein 4; ipilimumab) and anti–PD-1 (anti-programmed cell death protein 1; nivolumab; pembrolizumab), but the best clinical CD8 T cell | costimulation | OX40 | CTLA-4 | anti–DEC-205/HER2 results are coming from combination immunotherapy. Our re- search demonstrates that aOX40 (anti-CD134)/aCTLA-4 immuno- romoting a robust CD8 T-cell response is vital for the gen- therapy can lead to a potentially tumor-promoting Th2-cytokine Peration of an effective antitumor immune response. How- milieu (IL-4, IL-5, IL-13) when relying on endogenous antigen ever, immunosuppressive mechanisms used by the tumor result presentation. However, aOX40/aCTLA-4 treatment combined – in the exhaustion of tumor-infiltrating lymphocytes (TIL), lead- with a tumor antigen-specific vaccine, DEC-205 (anti dendritic and – ing to cytotoxic T-cell anergy and dysfunction. To overcome this epithelial cells, 205 kDa) HER2 (human epidermal growth factor dysfunction, investigators have had considerable success using receptor 2), promoted robust tumor infiltration by effector CD8 immune checkpoint inhibitors, such as aCTLA-4 (cytotoxic T cells and restored Th1 polarization of CD4 T cells, leading to T-lymphocyte–associated protein 4) mAbs, to promote T-cell improved overall survival in a mammary carcinoma model. This function. CTLA-4, a negative regulatory molecule on the surface study has direct relevance for the design of combination therapy of T cells, is indispensable for preventing the expansion and trials in patients. activation of autoreactive T cells. Inhibition of this surface re- – Author contributions: S.N.L. and W.L.R. designed research; S.N.L., M.J.K., M.J.M., I.F.H.-M., ceptor using antagonist aCTLA-4 mAb augmented effector CD4 and M.F. performed research; S.N.L. and W.L.R. analyzed data; and S.N.L. and W.L.R. and CD8 T-cell responses and inhibited or reduced the sup- wrote the paper. pressive function of Treg cells (1–5). However, only a subset of The authors declare no conflict of interest. patients treated with aCTLA-4 mAb exhibit an objective clinical This article is a PNAS Direct Submission. L.Z. is a guest editor invited by the Editorial response (6). Board. Checkpoint blockade targets T-cell coinhibitory molecules, but Freely available online through the PNAS open access option. other strategies targeting costimulatory molecules, such as the 1To whom correspondence should be addressed. Email: [email protected]. TNF receptor family member OX40 (CD134), have demon- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. INFLAMMATION IMMUNOLOGY AND strated success in promoting tumor regression in a wide variety 1073/pnas.1510518113/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1510518113 PNAS | Published online January 4, 2016 | E319–E327 Downloaded by guest on September 29, 2021 − − therapeutic efficacy, because inhibition of IL-4 with aOX40/ The expansion of wild-type or OX40 / OT-I cells in animals re- aCTLA-4 treatment significantly improved survival (13). Others ceiving combination therapy was analyzed by flow cytometry. OX40 have shown that a dominant Th2 cytokine response reduced the expression on CD8 T cells was required for optimal expansion, and + + efficacy of treatment, whereas a Th1-skewed immune response its expression enhanced the total number of Ki-67 ,granzymeB , + + + resulted in more favorable outcomes (20–23). IFNγ ,TNFα ,andIL-2 cells (Fig. 2A); we observed minimal We hypothesized that dendritic cell-targeted vaccination against change in the percentage of these populations relative to controls a tumor-associated antigen in conjunction with combination (Fig. 2B). We also confirmed OX40 expression on CD8 T cells from aOX40/aCTLA-4 mAb immunotherapy would be sufficient to the TIL of mice bearing TUBO mammary carcinomas (Figs. S1B promote a cytotoxic antitumor T-cell response, redirect a Th2 bias and S2A) and of TRAMP (transgenic adenocarcinoma of the in CD4 T cells, and improve survival in mice with established mouse prostate) mice with spontaneous prostate adenocarcinoma tumors. Here, we report that vaccination using anti–DEC-205/ (Fig. S3B). HER2 (human epidermal growth factor receptor 2) mAb along Previous studies demonstrated that CTLA-4 expression on CD4 with combination aOX40/aCTLA-4 mAbs significantly expanded T cells is required to augment CD8 T-cell function indirectly (1, 2). effector CD8 T cells, resulting in a more favorable Th1 cytokine To assess the role of CTLA-4 expression on CD8 T cells, we used profile and inducing a critical accumulation of effector T cells in humanized CTLA-4 knock-in (huCTLA-4) mice engineered to the tumor, with increased tumor-free survival relative to either express only the extracellular portion of the human CTLA-4 re- therapy alone. Moreover, combination therapy with vaccination ceptor, thereby preventing them from responding to mouse reversed T-cell anergy and promoted a robust effector T-cell aCTLA-4 mAb (2). Animals were treated with combination ther- response to a tumor-associated antigen in a spontaneous ade- apy following adoptive transfer of OT-I cells; as expected, nocarcinoma model. huCTLA-4 mice treated with mouse aCTLA-4 mAb had no change in OT-I expansion relative to IgG controls (Fig. 2C). Although Results we still observed an additive effect of combination therapy over Combined aOX40 and aCTLA-4 Therapy Significantly Enhanced monotherapy alone in huCTLA-4
Load more

Recommended publications
  • Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species
    International Journal of Molecular Sciences Review Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species Mohammed Yusuf Zanna 1 , Abd Rahaman Yasmin 1,2,* , Abdul Rahman Omar 2,3 , Siti Suri Arshad 3, Abdul Razak Mariatulqabtiah 2,4 , Saulol Hamid Nur-Fazila 3 and Md Isa Nur Mahiza 3 1 Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] 2 Laboratory of Vaccines and Biomolecules, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (A.R.O.); [email protected] (A.R.M.) 3 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (S.S.A.); [email protected] (S.H.N.-F.); [email protected] (M.I.N.M.) 4 Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia * Correspondence: [email protected]; Tel.: +603-8609-3473 or +601-7353-7341 Abstract: Dendritic cells (DCs) are cells derived from the hematopoietic stem cells (HSCs) of the bone marrow and form a widely distributed cellular system throughout the body. They are the most effi- cient, potent, and professional antigen-presenting cells (APCs) of the immune system, inducing and dispersing a primary immune response by the activation of naïve T-cells, and playing an important role in the induction and maintenance of immune tolerance under homeostatic conditions. Thus, this Citation: Zanna, M.Y.; Yasmin, A.R.; review has elucidated the general aspects of DCs as well as the current dynamic perspectives and Omar, A.R.; Arshad, S.S.; distribution of DCs in humans and in various species of animals that includes mouse, rat, birds, dog, Mariatulqabtiah, A.R.; Nur-Fazila, cat, horse, cattle, sheep, pig, and non-human primates.
    [Show full text]
  • Acting on the CCR1 Receptor Mediates Neutrophil Migration in Immune Inflammation Via Sequential ␣ Release of TNF- and LTB4 Cleber D
    MIP-1␣[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential ␣ release of TNF- and LTB4 Cleber D. L. Ramos,* Claudio Canetti,*,† Janeusa T. Souto,‡,§ Joa˜ o S. Silva,‡ Cory M. Hogaboam,¶ Sergio H. Ferreira,* and Fernando Q. Cunha*,1 Departments of *Pharmacology and ‡Biochemistry and Immunology, School of Medicine of Ribeira˜o Preto, University of Sa˜o Paulo, Brazil; §Department of Microbiology and Parasitology, Federal University of Rio Grande do Norte, Natal, RN, Brazil; and †Division of Pulmonary & Critical Care Medicine and ¶Department of Pathology, University of Michigan, Ann Arbor Abstract: In the present study, we investigated nists might have a therapeutic potential. J. Leukoc. the involvement of macrophage-inflammatory pro- Biol. 78: 167–177; 2005. tein-1␣ (MIP-1␣)[CC chemokine ligand 3 (CCL3)], MIP-1␤[CCL4], regulated on activation, normal Key Words: chemokines ⅐ chemokine receptors ⅐ chemotaxis T expressed and secreted (RANTES)[CCL5], and CC chemokine receptors (CCRs) on neutrophil mi- gration in murine immune inflammation. Previ- INTRODUCTION ously, we showed that ovalbumin (OVA)-triggered neutrophil migration in immunized mice depends on the sequential release of tumor necrosis factor Neutrophil migration is a complex process, which results ␣ ␣ mainly from the release of neutrophil chemotactic factors by (TNF- ) and leukotriene B4 (LTB4). Herein, we show increased mRNA expression for MIP- resident cells, inducing rolling and adhesion of neutrophils on 1␣[CCL3], MIP-1␤[CCL4], RANTES[CCL5], and endothelial cells, followed by their transmigration to the ex- travascular space [1, 2]. Apart from its importance in host CCR1 in peritoneal cells harvested from OVA-chal- defense, the migration of neutrophils to the inflammatory site lenged, immunized mice, as well as MIP-1␣[CCL3] is, at least in part, responsible for tissue damage observed in and RANTES[CCL5] but not MIP-1␤[CCL4] proteins several inflammatory diseases such as rheumatoid arthritis, in the peritoneal exudates.
    [Show full text]
  • Bioinformatics Identification of CCL8/21 As Potential Prognostic
    Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang ([email protected]) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC.
    [Show full text]
  • Association of Chemokine CCL5 and Systemic Malignancies
    J Hum Genet (2008) 53:377–378 DOI 10.1007/s10038-008-0270-6 LETTER TO THE EDITOR Association of chemokine CCL5 and systemic malignancies Shailendra Kapoor Received: 28 January 2008 / Accepted: 8 February 2008 / Published online: 27 March 2008 Ó The Japan Society of Human Genetics and Springer 2008 To the Editor CCL5 levels are also increased in a wide spectrum of The article by Konta et al. (2008) on the relationship other diseases, such as idiopathic inflammatory myopathies between CC chemokine ligand 5 (CCL5) genotype and (Civatte et al. 2005) and chronic gastritis (Ohtani et al. urinary albumin excretion in the nondiabetic Japanese 2004). The recent study by Konta et al. further adds to general population is highly interesting. The study by diseases in which CCL5 plays a major pathogenetic role. Konta et al. adds to the growing array of pathological Further studies are needed to identify potent and safe conditions in which CCL5 plays a major role. Interestingly, inhibitors of CCL5 for better management of these diseases CCL5 has recently been implicated in the etiopathogenesis ranging from breast cancer to nondiabetic albuminuria. of a number of systemic malignancies. For instance, Luboshits et al. (1999), in a recent study, have shown that advanced breast cancers are associated References with increased expression of CCL5. CCL5 has also been shown to be a significant predictor of progression in Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A (2008) Expression of CCR5 receptors patients with stage II breast cancer (Hahoshen et al. 2006). on Reed-Sternberg cells and Hodgkin lymphoma cell lines: In another study, tumors that expressed higher levels of involvement of CCL5/Rantes in tumor cell growth and micro- CCL5 were more likely to metastasize in comparison with environmental interactions.
    [Show full text]
  • Platelet-Derived Growth Factor Isoform Expression in Carbon Tetrachloride
    Laboratory Investigation (2008) 88, 1090–1100 & 2008 USCAP, Inc All rights reserved 0023-6837/08 $30.00 Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury Erawan Borkham-Kamphorst1, Evgenia Kovalenko1, Claudia RC van Roeyen2, Nikolaus Gassler3, Michael Bomble1, Tammo Ostendorf 2,Ju¨rgen Floege2, Axel M Gressner1 and Ralf Weiskirchen1 Platelet-derived growth factor (PDGF) has an essential role in liver fibrogenesis, as PDGF-B and -D both act as potent mitogens on culture-activated hepatic stellate cells (HSCs). Induction of PDGF receptor type-b (PDGFRb) in HSC is well documented in single-dose carbon tetrachloride (CCl4)-induced acute liver injury. Of the newly discovered isoforms PDGF- C and -D, only PDGF-D shows significant upregulation in bile duct ligation (BDL) models. We have now investigated the expression of PDGF isoforms and receptors in chronic liver injury in vivo after long-term CCl4 treatment and demonstrated that isolated hepatocytes have the requisite PDGF signaling pathways, both in the naive state and when isolated from CCl4-treated rats. In vivo, PDGF gene expression showed upregulation of all PDGF isoforms and receptors, with values peaking at 4 weeks and decreasing to near basal levels by 8 and 12 weeks. Interestingly, PDGF-C increased significantly when compared to BDL-models. PDGF-A, PDGF-C and PDGF receptor type-a (PDGFRa) correlated closely with in- flammation and steatosis. Immunohistochemistry revealed expression of PDGF-B, -C and -D in areas corresponding to centrilobular necrosis, inflammation and fibrosis, whereas PDGF-A localized in regenerative hepatocytes. PDGFRb was identified along the fibrotic septa, whereas PDGFRa showed positive staining in fibrotic septa and regenerative hepa- tocytes.
    [Show full text]
  • 5-O-Demethylnobiletin Alleviates Ccl4-Induced Acute Liver Injury by Equilibrating ROS-Mediated Apoptosis and Autophagy Induction
    International Journal of Molecular Sciences Article 5-O-Demethylnobiletin Alleviates CCl4-Induced Acute Liver Injury by Equilibrating ROS-Mediated Apoptosis and Autophagy Induction Sukkum Ngullie Chang 1,2,†, Se Ho Kim 2,3,†, Debasish Kumar Dey 1, Seon Min Park 2, Omaima Nasif 4, Vivek K. Bajpai 5,*, Sun Chul Kang 1, Jintae Lee 3,* and Jae Gyu Park 2,* 1 Department of Biotechnology, Daegu University, Gyeongsan 38453, Korea; [email protected] (S.N.C.); [email protected] (D.K.D.); [email protected] (S.C.K.) 2 Advanced Bio Convergence Center (ABCC), Pohang Technopark Foundation, Pohang 37668, Korea; [email protected] (S.H.K.); [email protected] (S.M.P.) 3 School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Korea 4 Department of Physiology, College of Medicine, King Saud University (Medical City), King Khalid University Hospital, P.O. Box 2925, Riyadh 11461, Saudi Arabia; [email protected] 5 Department of Energy and Materials Engineering, Dongguk University-Seoul, 30 Pildong-ro 1-gil, Seoul 04620, Korea * Correspondence: [email protected] (V.K.B.); [email protected] (J.T.L.); [email protected] (J.G.P.); Fax: +82-32-872-4046 (V.K.B.); +82-53-810-4631 (J.L.); +82-54-223-2780 (J.G.P.) † Contributed equally to this work. Abstract: Polymethoxyflavanoids (PMFs) have exhibited a vast array of therapeutic biological properties. 5-O-Demethylnobiletin (5-DN) is one such PMF having anti-inflammatory activity, yet its role in hepatoprotection has not been studied before. Results from in vitro study revealed that Citation: Chang, S.N.; Kim, S.H.; 5-DN did not exert a high level of cytotoxicity on HepG2 cells at 40 µM, and it was able to rescue Dey, D.K.; Park, S.M.; Nasif, O.; HepG2 cell death induced by carbon tetrachloride (CCl4).
    [Show full text]
  • The CCL7-CCL2-CCR2 Axis Regulates IL-4 Production in Lungs and Fungal Immunity Wendy A
    The CCL7-CCL2-CCR2 Axis Regulates IL-4 Production in Lungs and Fungal Immunity Wendy A. Szymczak and George S. Deepe, Jr This information is current as J Immunol 2009; 183:1964-1974; Prepublished online 8 July of September 29, 2021. 2009; doi: 10.4049/jimmunol.0901316 http://www.jimmunol.org/content/183/3/1964 Downloaded from References This article cites 57 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/183/3/1964.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The CCL7-CCL2-CCR2 Axis Regulates IL-4 Production in Lungs and Fungal Immunity1 Wendy A. Szymczak*† and George S. Deepe, Jr.2*‡ Expression of the chemokine receptor CCR2 can be detrimental or beneficial for infection resolution.
    [Show full text]
  • Stabilin-1 Expression Defines a Subset of Macrophages That Mediate Tissue Homeostasis and Prevent Fibrosis in Chronic Liver Injury
    Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury Pia Rantakaria,1, Daniel A. Pattenb,1, Joona Valtonena, Marika Karikoskia, Heidi Gerkea, Harriet Dawesb, Juha Laurilaa, Steffen Ohlmeierc, Kati Elimad, Stefan G. Hübschere, Chris J. Westonb, Sirpa Jalkanena, David H. Adamsb, Marko Salmia, and Shishir Shettyb,2 aMediCity Research Laboratory and Department of Medical Microbiology and Immunology, University of Turku, FI-20520, Turku, Finland; bNational Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver Research, Institute of Immunology and Immunotherapy, Universityof Birmingham, Birmingham B15 2TT, United Kingdom; cProteomics Core Facility, Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, FI-90014, Oulu, Finland; dMediCity Research Laboratory, Department of Medical Biochemistry and Genetics, University of Turku, FI-20520, Turku, Finland; and eSchool of Cancer Sciences, University of Birmingham B15 2TT, Birmingham, United Kingdom Edited by Jeffrey W. Pollard, Albert Einstein College of Medicine, Bronx, NY, and accepted by Editorial Board Member Brigid L. Hogan June 17, 2016 (received for review March 29, 2016) Macrophages are key regulators of fibrosis development and reso- Previous studies have demonstrated multiple stabilin-1 ligands, lution. Elucidating the mechanisms by which they mediate this including oxLDL (7), the ECM glycoprotein osteonectin (8), and process is crucial for establishing their therapeutic potential. Here, placental lactogen (9), suggesting that stabilin-1 functions as a we use experimental models of liver fibrosis to show that deficiency homeostatic scavenger receptor. We have previously reported of the scavenger receptor, stabilin-1, exacerbates fibrosis and delays stabilin-1 expression by HSEC, but not by resident liver macro- resolution during the recovery phase.
    [Show full text]
  • Fas/Fasl Mediates NF-Κbp65/PUMA-Modulated
    Tan et al. Cell Death and Disease (2021) 12:474 https://doi.org/10.1038/s41419-021-03749-x Cell Death & Disease ARTICLE Open Access Fas/FasL mediates NF-κBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis Siwei Tan 1,2,XianzhiLiu1, Lingjun Chen1, Xiaoqin Wu1,LiTao1,XuemeiPan1,ShuyanTan1, Huiling Liu1,JieJiang1 and Bin Wu 1,2 Abstract Fas/Fas ligand (FasL)-mediated cell apoptosis involves a variety of physiological and pathological processes including chronic hepatic diseases, and hepatocytes apoptosis contributes to the development of liver fibrosis following various causes. However, the mechanism of the Fas/FasL signaling and hepatocytes apoptosis in liver fibrogenesis remains unclear. The Fas/FasL signaling and hepatocytes apoptosis in liver samples from both human sections and mouse models were investigated. NF-κBp65 wild-type mice (p65f/f), hepatocytes specific NF-κBp65 deletion mice (p65Δhepa), p53-upregulated modulator of apoptosis (PUMA) wild-type (PUMA-WT) and PUMA knockout (PUMA-KO) littermate models, and primary hepatic stellate cells (HSCs) were also used. The mechanism underlying Fas/FasL-regulated hepatocytes apoptosis to drive HSCs activation in fibrosis was further analyzed. We found Fas/FasL promoted PUMA- mediated hepatocytes apoptosis via regulating autophagy signaling and NF-κBp65 phosphorylation, while inhibition of autophagy or PUMA deficiency attenuated Fas/FasL-modulated hepatocytes apoptosis and liver fibrosis. Furthermore, NF-κBp65 in hepatocytes repressed PUMA-mediated hepatocytes apoptosis via regulating the Bcl-2 κ fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; family, while NF- Bp65 de ciency in hepatocytes promoted PUMA-mediated hepatocytes apoptosis and enhanced apoptosis-linked inflammatory response, which contributed to the activation of HSCs and liver fibrogenesis.
    [Show full text]
  • CCL3L1 and CCL4L1: Variable Gene Copy Number in Adolescents with and Without Human Immunodeficiency Virus Type 1 (HIV-1) Infection
    Genes and Immunity (2007) 8, 224–231 & 2007 Nature Publishing Group All rights reserved 1466-4879/07 $30.00 www.nature.com/gene ORIGINAL ARTICLE CCL3L1 and CCL4L1: variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection W Shao1, J Tang2, W Song1, C Wang1,YLi2, CM Wilson2,3 and RA Kaslow1,2 1Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA and 3Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA As members of the chemokine family, macrophage inflammatory protein 1 alpha (MIP-1a) and MIP-1b are unique in that they both consist of non-allelic isoforms encoded by different genes, namely chemokine (C-C motif) ligand 3 (CCL3), CCL4, CCL3- like 1 (CCL3L1) and CCL4L1. The products of these genes and of CCL5 (encoding RANTES, i.e., regulated on activation, normal T expressed and secreted) can block or interfere with human immunodeficiency virus type 1 (HIV-1) infection through competitive binding to chemokine (C-C motif) receptor 5 (CCR5). Our analyses of 411 adolescents confirmed that CCL3 and CCL4 genes occurred invariably as single copies (two per diploid genome), whereas the copy numbers of CCL3L1 and CCL4L1 varied extensively (0–11 and 1–6 copies, respectively). Neither CCL3L1 nor CCL4L1 gene copy number variation showed appreciable impact on susceptibility to or control of HIV-1 infection. Within individuals, linear correlation between CCL3L1 and CCL4L1 copy numbers was moderate regardless of ethnicity (Pearson correlation coefficients ¼ 0.63–0.65, Po0.0001), suggesting that the two loci are not always within the same segmental duplication unit.
    [Show full text]
  • Carbon Tetrachloride-Induced Hepatic Injury Through Formation of Oxidized
    Laboratory Investigation (2013) 93, 218–229 & 2013 USCAP, Inc All rights reserved 0023-6837/13 $32.00 Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC/NF-kB pathway Kentaro Toriumi1, Yosuke Horikoshi1, R Yoshiyuki Osamura1, Yorihiro Yamamoto2, Naoya Nakamura1 and Susumu Takekoshi1,3 Protein kinase C (PKC) participates in signal transduction, and its overactivation is involved in various types of cell injury. PKC depends on diacylglycerol (DAG) for its activation in vivo We have previously reported that DAG peroxides (DAG- O(O)H) activate PKC in vitro more strongly than unoxidized DAG, suggesting that DAG-O(O)H, if generated in vivo under oxidative stress, would act as an aberrant signal transducer. The present study examined whether DAG-O(O)H are formed in carbon tetrachloride (CCl4)-induced acute rat liver injury in association with activation of the PKC/nuclear factor (NF)-kB pathway. A single subcutaneous injection of CCl4 resulted in a marked increase in hepatic DAG-O(O)H content. At the molecular level, immunohistochemistry and subcellular fractionation combined with immunoblotting localized PKCa, bI, bII and d isoforms to cell membranes, while immunoblotting showed phosphorylation of the p65 subunit of NF-kB, and immunoprecipitation using isoform-specific anti-PKC antibodies revealed specific association of PKCa and p65. In addi- tion, expression of tumor necrosis factor a (TNFa) and neutrophil invasion increased in the CCl4-treated rats. Furthermore, we demonstrated that Vitamin E, one of the most important natural antioxidants that suppresses peroxidation of membrane lipids, significantly inhibited the CCl4-induced increase in hepatic DAG-O(O)H content and TNFa expression as well as phosphorylation of PKCa and p65.
    [Show full text]
  • Monocyte/Macrophage-Derived CCL11 Inflammatory + CCR2 High
    Colonic Eosinophilic Inflammation in Experimental Colitis Is Mediated by Ly6C high CCR2+ Inflammatory Monocyte/Macrophage-Derived CCL11 This information is current as of October 1, 2021. Amanda Waddell, Richard Ahrens, Kris Steinbrecher, Burke Donovan, Marc E. Rothenberg, Ariel Munitz and Simon P. Hogan J Immunol 2011; 186:5993-6003; Prepublished online 15 April 2011; Downloaded from doi: 10.4049/jimmunol.1003844 http://www.jimmunol.org/content/186/10/5993 Supplementary http://www.jimmunol.org/content/suppl/2011/04/15/jimmunol.100384 http://www.jimmunol.org/ Material 4.DC1 References This article cites 67 articles, 28 of which you can access for free at: http://www.jimmunol.org/content/186/10/5993.full#ref-list-1 Why The JI? Submit online. by guest on October 1, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Colonic Eosinophilic Inflammation in Experimental Colitis Is Mediated by Ly6Chigh CCR2+ Inflammatory Monocyte/Macrophage-Derived CCL11 Amanda Waddell,* Richard Ahrens,* Kris Steinbrecher,† Burke Donovan,* Marc E.
    [Show full text]